AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Policy Tracker · Official source

United States

Where this status comes from, in the government's own words.

Current status

Pending bill

A bill to change the law is under consideration.

Not yet checked against the official law — treat as provisional.

Official law

21 CFR 1308.11 — Schedule I (Controlled Substances Act, 21 U.S.C. 812)

Published by ecfr.gov

Show on the map Country overview All legal sources

Loading source…